zinc and ring finger 3Genealiases: BK747E2.3 · RNF203
Q-omics provides the consensus-scored ZNRF3 profile across patient tissues and cancer cell-line models. ZNRF3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNRF3 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, ZNRF3 RNA expression shows 19,190 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where ZNRF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNRF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNRF3 survival associations across molecular data types. ZNRF3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNRF3 RNA expression–survival associations across cancer types. High ZNRF3 expression shows favorable associations in KIRC, ESCA, LUAD, UCEC, SCLC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNRF3 RNA expression.
This table summarizes ZNRF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNRF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNRF3 shows lower tumor expression in KIRC and higher tumor expression in COAD, HNSC, BLCA, READ and LUSC. The COAD box plot shows higher ZNRF3 RNA expression in tumor versus normal tissue (log2 FC = +0.346, t-test p < 0.001).
This table shows molecular features associated with ZNRF3 in patient tissues and cancer cell lines. In patient samples, ZNRF3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNRF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
